We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note
Read MoreHide Full Article
Viking Therapeutics, Inc. (VKTX - Free Report) ended the recent trading session at $29.52, demonstrating a -1.44% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.45%. On the other hand, the Dow registered a loss of 1.21%, and the technology-centric Nasdaq decreased by 0.01%.
Shares of the company have depreciated by 10.25% over the course of the past month, underperforming the Medical sector's loss of 0.29%, and the S&P 500's loss of 2.43%.
Analysts and investors alike will be keeping a close eye on the performance of Viking Therapeutics, Inc. in its upcoming earnings disclosure. In that report, analysts expect Viking Therapeutics, Inc. to post earnings of -$1 per share. This would mark a year-over-year decline of 23.46%.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$4.47 per share and revenue of $0 million, indicating changes of -40.13% and 0%, respectively, compared to the previous year.
Investors should also take note of any recent adjustments to analyst estimates for Viking Therapeutics, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. At present, Viking Therapeutics, Inc. boasts a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 165, positioning it in the bottom 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note
Viking Therapeutics, Inc. (VKTX - Free Report) ended the recent trading session at $29.52, demonstrating a -1.44% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.45%. On the other hand, the Dow registered a loss of 1.21%, and the technology-centric Nasdaq decreased by 0.01%.
Shares of the company have depreciated by 10.25% over the course of the past month, underperforming the Medical sector's loss of 0.29%, and the S&P 500's loss of 2.43%.
Analysts and investors alike will be keeping a close eye on the performance of Viking Therapeutics, Inc. in its upcoming earnings disclosure. In that report, analysts expect Viking Therapeutics, Inc. to post earnings of -$1 per share. This would mark a year-over-year decline of 23.46%.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$4.47 per share and revenue of $0 million, indicating changes of -40.13% and 0%, respectively, compared to the previous year.
Investors should also take note of any recent adjustments to analyst estimates for Viking Therapeutics, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. At present, Viking Therapeutics, Inc. boasts a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 165, positioning it in the bottom 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.